Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: Impact of cyclooxygenase selectivity

被引:101
作者
Carbone, LD
Tylavsky, FA
Cauley, JA
Harris, TB
Lang, TF
Bauer, DC
Barrow, KD
Kritchevsky, SB
机构
[1] Univ Tennessee, Ctr Hlth Sci, Dept Med, Memphis, TN 38163 USA
[2] Univ Tennessee, Ctr Hlth Sci, Dept Prevent Med, Memphis, TN 38163 USA
[3] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA
[4] NIA, Epidemiol Demography & Biometry Program, Bethesda, MD USA
[5] Univ Calif San Francisco, Dept Radiol, San Francisco, CA 94143 USA
[6] Univ Calif San Francisco, Prevent Sci Grp, San Francisco, CA 94143 USA
关键词
nonsteroidal anti-inflammatory drugs; bone; aspirin; cyclo-oxygenase; elderly;
D O I
10.1359/jbmr.2003.18.10.1795
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BMD was examined in users of NSAIDs (by COX selectivity) and aspirin in the Health ABC cohort (n = 2853). Significantly higher BMD was found in users of relative COX-2 selective NSAIDs with aspirin (COX-2/ASA) compared with nonusers. This suggests a role for COX-2/ASA in osteoporosis. Introduction: The purpose of this study was to determine the relationship of nonsteroidal anti-inflammatory drug (NSAID) use, by cyclo-oxygenase selectivity (COX), and aspirin use on bone mineral density (BMD) in participants from the Health, Aging, and Body Composition (Health ABC) population-based cohort. It is known that NSAIDs inhibit the COX enzyme and decrease production of Prostaglandins, which are involved in regulation of bone turnover. COX has two isoforms, COX-1 and COX-2. Production of Prostaglandins associated with bone loss is primarily mediated through the COX-2 pathway. In addition, aspirin may have effects on bone independent of the prostaglandin pathway. Materials and Methods: NSAID (by COX selectivity) and aspirin use and BMD were assessed in 2853 adults (49.5% women, 50.5% men; 43.1% black, 56.9% white; mean age: 73.6 years) from the Health ABC cohort. For the purposes of this analysis, relative COX-1 selective NSAIDs were defined as having a ratio of COX-1 IC50 to COX-2 IC50 of > 1 in whole blood, and relative COX-2 selective NSAIDs were defined as having a ratio of COX-1 IC50 to COX-2 IC50 of < 1 in whole blood. Analysis of covariance, was used to compare BMD across each NSAID use and aspirin use category adjusting for age, race, gender, weight, height, study site, calcium and vitamin D supplementation, Womac score, history of rheumatoid arthritis, history of arthritis other than rheumatoid, and smoking status. Results: After adjustment for possible confounders, current use of relative COX-2 selective NSAIDs with aspirin was associated with higher BMD at the whole body (4.2%, 1.2-7.3 CI) and total hip (4.6%, 0.5-8.8 CI) by DXA and at both trabecular (34.1%, 15.4-52.7 CI) and cortical spine (12.8%, 2.3-23.3 CI) by quantitative computed tomography. Conclusions: Our data suggest that the combination of relative COX-2 selective NSAIDs and aspirin is associated with higher BMD at multiple skeletal sites in men and women.
引用
收藏
页码:1795 / 1802
页数:8
相关论文
共 43 条
[1]   Synergistic inhibition of cyclooxygenase-2 expression by vitamin E and aspirin [J].
Abate, A ;
Yang, G ;
Dennery, PA ;
Oberle, S ;
Schröder, H .
FREE RADICAL BIOLOGY AND MEDICINE, 2000, 29 (11) :1135-1142
[2]   The pleiotropic functions of aspirin: mechanisms of action [J].
Amin, AR ;
Attur, MG ;
Pillinger, M ;
Abramson, SB .
CELLULAR AND MOLECULAR LIFE SCIENCES, 1999, 56 (3-4) :305-312
[3]   Evidence for a pathogenic role of nitric oxide in inflammation-induced osteoporosis [J].
Armour, KE ;
Van't Hof, RJ ;
Grabowski, PS ;
Reid, DM ;
Ralston, SH .
JOURNAL OF BONE AND MINERAL RESEARCH, 1999, 14 (12) :2137-2142
[4]  
Bauer DC, 1996, J BONE MINER RES, V11, P29
[5]  
Bellamy N, 1995, WOMAC OSTEOARTHRITIS
[6]   A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors [J].
Brideau, C ;
Kargman, S ;
Liu, S ;
Dallob, AL ;
Ehrich, EW ;
Rodger, IW ;
Chan, CC .
INFLAMMATION RESEARCH, 1996, 45 (02) :68-74
[7]   Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. [J].
Catella-Lawson, F ;
Reilly, MP ;
Kapoor, SC ;
Cucchiara, AJ ;
DeMarco, S ;
Tournier, B ;
Vyas, SN ;
FitzGerald, GA .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (25) :1809-1817
[8]   A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study [J].
Chesnut, CH ;
Silverman, S ;
Andriano, K ;
Genant, H ;
Gimona, A ;
Harris, S ;
Kiel, D ;
LeBoff, M ;
Maricic, M ;
Miller, P ;
Moniz, C ;
Peacock, M ;
Richardson, P ;
Watts, N ;
Baylink, D .
AMERICAN JOURNAL OF MEDICINE, 2000, 109 (04) :267-276
[9]  
Chiang N, 1998, J PHARMACOL EXP THER, V287, P779
[10]   ASPIRIN TRIGGERS PREVIOUSLY UNDESCRIBED BIOACTIVE EICOSANOIDS BY HUMAN ENDOTHELIAL CELL-LEUKOCYTE INTERACTIONS [J].
CLARIA, J ;
SERHAN, CN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (21) :9475-9479